Clinical trials: Acute Lung Injury
Acute Respiratory Distress Syndrome
Reevaluation Of Systemic Early Neuromuscular Blockade
This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival.
- Trial name
- ROSE (NCT02509078)
- Testing
- Cisatracurium Besylate
- Where
- 44 sites in United States
- Volunteers
- 1,008 people
- Sponsor
- Massachusetts General Hospital
Acute Respiratory Distress Syndrome, Sepsis
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
This study is a multi-center, randomized, partially double-blind, and placebo-controlled Phase Ib clinical trial of inhaled CO (iCO) for the treatment of sepsis-induced acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04870125
- Testing
- Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Brigham and Women's Hospital
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
Respiratory Distress Syndrome, Adult
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS).
- Trial name
- INTEREST (NCT02622724)
- Testing
- Interferon beta-1a
- Where
- 71 sites in Belgium, Czechia and 6 more
- Volunteers
- 301 people
- Sponsor
- Faron Pharmaceuticals Ltd
Rib Fracture, Rib Fracture Multiple
Orthosis of Acute Traumatic Rib Fractures Via RibFx Belt for Pain Alleviation and Improved Pulmonary Function
Acute traumatic rib fractures are a common issue for patients of trauma surgeons. They inflict substantial morbidity, the most dreaded and consequential of which are pulmonary complications.
- Conditions
- Rib Fracture, Rib Fracture Multiple, Trauma, Trauma Chest
- Trial name
- RibFx (NCT03846024)
- Testing
- RibFx Orthosis Belt
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Vermont Medical Center
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
Acute Respiratory Distress Syndrome, Coronavirus Infection
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04478071
- Testing
- vadadustat
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Respiratory Distress Syndrome, Critical Illness
A Study Promoting Critical Illness Recovery in the Elderly
This proposal will test the hypothesis that EARLY application of a novel early rehabilitation therapy in critically ill patients will improve functional outcomes, and change the functional trajectory of this population.
- Conditions
- Acute Respiratory Distress Syndrome, Critical Illness, Critical Care
- Trial name
- ASPIRE (NCT02963558)
- Testing
- cycle ergometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Ventilator Induced Lung Injury, Cardiac Disease
Intensive Alveolar Recruitment Protocol After Cardiac Surgery
The purpose of this study was to evaluate prospectively the impact of two protective mechanical ventilation strategies, both using low tidal volume ventilation (6 mL/kg/ibw) after cardiac surgery.
- Conditions
- Ventilator Induced Lung Injury, Cardiac Disease, Acute Lung Injury
- Trial name
- NCT01502332
- Testing
- Intensive Alveolar Recruitment, Moderate Alveolar Recruitment
- Where
- Brazil
- Volunteers
- 320 people
- Sponsor
- University of Sao Paulo
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the…
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04973488
- Testing
- Therapeutic plasma exchange
- Where
- Romania
- Volunteers
- 38 people
- Sponsor
- Novacescu Alexandru
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
ARDS
Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)
Proof-of-concept study addressing the feasibility of awake ECMO (v/v) in patients with acute respiratory failure
- Trial name
- NCT01669863
- Testing
- ECMO, ECMO in non-intubated patients
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Hannover Medical School
Acute Respiratory Distress Syndrome
Open Lung Ventilation in ARDS: The PHARLAP Trial
Some people develop the condition called acute respiratory distress syndrome (ARDS). This is a condition where the lungs have become injured from one of a number of various causes, and do not work as they normally do to provide…
- Trial name
- PHARLAP (NCT01667146)
- Testing
- PHARLAP mechanical ventilation strategy, Control group mechanical ventilation strategy
- Where
- 27 sites in Australia, Ireland and 3 more
- Volunteers
- 115 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Efficacy and Safety of Itolizumab in COVID-19 Complications
Randomized, Parallel Group, Active Controlled Trial
- Conditions
- Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
- Trial name
- NCT04475588
- Testing
- Itolizumab IV infusion, Best supportive care (BSC)
- Where
- 4 sites in India
- Volunteers
- 32 people
- Sponsor
- Biocon Limited
SARS-CoV-2 Infection, Acute Kidney Injury
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+)…
- Trial name
- NIRVANA (NCT04818216)
- Testing
- Nicotinamide riboside
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Severe Sepsis, Acute Lung Injury
Citrulline in Severe Sepsis
This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to placebo in patients with severe sepsis at risk for or…
- Trial name
- NCT01474863
- Testing
- High Dose Citrulline, Low Dose Citrulline
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Vanderbilt University
COVID-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
- Trial name
- NCT04315298
- Testing
- Sarilumab
- Where
- 62 sites in United States
- Volunteers
- 1,912 people
- Sponsor
- Regeneron Pharmaceuticals
Lung Injury, Acute (ALI), Respiratory Distress Syndrome, Acute (ARDS)
Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are similar conditions in which the lungs are critically injured by another inflammatory process in the body.
- Trial name
- CEASE (NCT00796419)
- Testing
- 5% human albumin, 6% hetastarch
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Emory University
Acute Lung Injury
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
The purpose of this study is to test a treatment that tries to reduce the amount of fluid in the lungs of subjects with acute lung injury to see if this is helpful.
- Trial name
- HEAL (NCT00624650)
- Testing
- Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Oregon Health and Science University